Sacituzumab Tirumotecan
Antibody–drug conjugate
Also known as SKB264, MK-2870
Evidence outlook
Approved: Unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer after... (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Partial signal
Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USHR+/HER2- Metastatic Breast Cancer · Phase 3 · investigational in the USOvarian Cancer · Phase 3 · investigational in the USCervical Cancer · Phase 3 · investigational in the USBladder Cancer · Phase 3 · investigational in the USEndometrial Cancer · Phase 3 · investigational in the US
Also approved (2)
- Unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced setting
- EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC after progression on EGFR-TKI therapy and platinum-based chemotherapy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05347134 NCT05347134 · Triple Negative Breast Cancer This was a randomized, adequately sized (n=254) phase 3 trial with an active chemotherapy comparator and a hard clinical endpoint (progression-free survival, reviewed independently), and it clearly succeeded, showing a large PFS benefit for sac-TMT over chemotherapy. However, the trial was open-label with no blinding of patients or investigators, which limits confidence in any endpoints subject to subjective influence, so despite the strong result this design element keeps the grade at moderate rather than the highest tier. Registry: NCT05347134 | 3 | Progression-free survival (PFS) (up to 24 months) 2023-11-30 | OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001 | Partial signal | link ↗ |
View 1 more trial
NCT06393374 NCT06393374 · Triple-Negative Breast Cancer Registry: NCT06393374 | 3 | Invasive Disease-Free Survival (iDFS) (Up to ~77 months) 2030-12-16 | In progress: results expected 16 Dec 2030 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (27)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (80)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
Other TROP2 drugs
Datopotamab Deruxtecan, Sacituzumab Govitecan, Sacituzumab drozuntecan, Tizetatug rezetecan, BL-M02D1 and 2 more. Compare all 8 TROP2 drugs
7 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Bladder Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan: this drug | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Enfortumab Vedotin | Approved | Antibody–drug conjugate | Nectin-4 | Partial signal | NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74) NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4) | |
| Nogapendekin Alfa Inbakicept (Anktiva) | Approved | Protein / enzyme therapeutic | IL-15 superagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tremelimumab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Visugromab | Phase 2 | Monoclonal antibody | GDF-15 | Weak signal | NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%. | |
| MK-3120 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2005 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Tuvutromstat | Phase 1 | Small molecule | MAT2A | not yet graded | No reviewed efficacy summary in this indication | |
| Avipendekin Pegol | —(overall) | Cytokine | IL-15 receptor | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(111 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Sacituzumab Tirumotecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (6)
November 2026 (1)
What to watch
December 2026 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (38)
January 2027 (2)
February 2027 (2)
March 2027 (1)
What to watch
April 2027 (2)
May 2027 (2)
June 2027 (4)
What to watch
What to watch
What to watch
What to watch
July 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
August 2027 (4)
What to watch
What to watch
What to watch
What to watch
September 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (12)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (35)
January 2028 (9)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
February 2028 (1)
What to watch
March 2028 (3)
What to watch
What to watch
What to watch
April 2028 (1)
What to watch
May 2028 (1)
What to watch
June 2028 (4)
What to watch
What to watch
What to watch
What to watch
August 2028 (5)
What to watch
What to watch
What to watch
What to watch
September 2028 (3)
What to watch
What to watch
What to watch
October 2028 (2)
What to watch
What to watch
November 2028 (1)
What to watch
December 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (13)
January 2029 (2)
What to watch
What to watch
April 2029 (1)
What to watch
July 2029 (1)
What to watch
August 2029 (2)
September 2029 (2)
What to watch
What to watch
October 2029 (2)
What to watch
What to watch
November 2029 (1)
What to watch
2030 (7)
January 2030 (1)
What to watch
March 2030 (3)
What to watch
What to watch
What to watch
April 2030 (1)
What to watch
May 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (4)
March 2031 (1)
What to watch
September 2031 (1)
What to watch
October 2031 (1)
What to watch
November 2031 (1)
What to watch
2032 (4)
January 2032 (1)
What to watch
February 2032 (1)
What to watch
May 2032 (1)
What to watch
June 2032 (1)
What to watch
2033 (2)
2034 (1)
February 2034 (1)
What to watch
2036 (1)
September 2036 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent